Floxsafe/Floxsafe IV Dosage/Direction for Use

Floxsafe: Posology (adults): The recommended dose is one 400 mg film-coated tablet once daily.
Renal/hepatic impairment: No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis.
There is insufficient data in patients with impaired liver function.
Other special populations: No adjustment of dosage is required in the elderly and in patients with low bodyweight.
Paediatric population: Moxifloxacin is contraindicated in children and adolescents (<18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established.
Method of administration: The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.
Duration of administration: Moxifloxacin 400 mg film-coated tablets should be used for the following treatment durations: Acute exacerbation of chronic bronchitis: 5-10 days.
Community acquired pneumonia: 10 days.
Acute bacterial sinusitis: 7 days.
Mild to moderate pelvic inflammatory disease: 14 days.
Moxifloxacin 400 mg film-coated tablets have been studied in clinical trials for up to 14 days treatment.
Sequential (intravenous followed by oral) therapy: In clinical studies with sequential therapy most patients switched from intravenous to oral therapy within 4 days (community-acquired pneumonia) or 6 days (complicated skin and skin structure infections). The recommended total duration of intravenous and oral treatment is 7-14 days for community-acquired pneumonia and 7-21 days for complicated skin and skin structure infections.
The recommended dose (400 mg once daily) and duration of therapy for the indication being treated should not be exceeded.
Floxsafe IV: For adult, the recommended dose is 400 mg moxifloxacin, infused into vein over 60 minutes once daily.
Renal impairment (Creatinine Clearance <30 mL/min/1.73 m²): No adjustment of dosage is required.
Duration: The duration of therapy depends the severity of infection or clinical response. The recommended durations are as follows.
Sequential therapy for Acute Bacterial Sinusitis (orally or as intravenous infusion): 7-14 days.
Sequential therapy for Acute Bacterial Exacerbation of Chronic Bronchitis (orally or as an intravenous infusion): 5 days.
Sequential therapy for Pneumonia (orally or as an intravenous infusion): 7-14 days.
Sequential therapy for Uncomplicated Skin and Skin Structure Infections (orally or as an intravenous infusion): 7 days.
Sequential therapy for Complicated Skin and Skin Structure Infections (orally or as an intravenous infusion): 7-21 days.
Sequential therapy for Complicated Intra-Abdominal Infections (orally or as an intravenous infusion): 5-14 days.